1013-22-5

Basic information

• Product Name: 1-(2,3-Dimethylphenyl)piperazine
• Synonyms: AKOS BBS-00003579;1-(2,3-DIMETHYLPHENYL)PIPERAZINE;TIMTEC-BB SBB003652;RARECHEM AH CK 0093;1-(2,3-xylyl)piperazine;1-(2,3-DIMETHYLPHENYL)-PIPERAZINE >98%;Piperazine, 1-(2,3-dimethylphenyl)-;1-(2,3-Dimethylphenyl)piperazine,99%
• CAS NO: 1013-22-5
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• EINECS: 213-794-0
• Product Categories: Piperaizine;API intermediates
• Mol File: 1013-22-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 95 °C
• Flash Point: 156.052 °C
• Appearance: Clear light yellow/Viscous Liquid
• Density: 1.031
• Vapor Pressure: 9.93E-05mmHg at 25°C
• Refractive Index: 1.5566-1.5606
• Storage Temp.: 0-6°C
• PKA: 9.05±0.10(Predicted)
• CAS DataBase Reference: 1-(2,3-Dimethylphenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,3-Dimethylphenyl)piperazine(1013-22-5)
• EPA Substance Registry System: 1-(2,3-Dimethylphenyl)piperazine(1013-22-5)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-21/22-36/37/38
• Safety Statements: 45-36/37/39-26-23-37
• Hazardous Substances Data: 1013-22-5(Hazardous Substances Data)

Usage

Chemical Properties

clear light yellow viscous liquid

InChI:InChI=1/C12H18N2/c1-10-4-3-5-12(11(10)2)14-8-6-13-7-9-14/h3-5,13H,6-9H2,1-2H3/p+1

Upstream product

• 80836-96-0 1-(2,3-dimethylphenyl)piperazine hydrochloride 

Downstream Products

• 189761-41-9 {2-[4-(2,3-dimethyl-phenyl)-piperazin-1-yl]-1-methyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 189761-50-0 {2-[4-(2,3-dimethyl-phenyl)-piperazin-1-yl]-1-methyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 516473-03-3 1-[(S)-N-tert-butyloxycarbonyl-N-methyltyrosyl]-4-(2,3-dimethylphenyl)piperazine 
• 180156-69-8 (2S)-(-)-1-(4-indolyloxy)-3-(4-(2,3-dimethylphenyl)piperazin-1-yl)-2-propanol ethanedioate 
• 1072849-76-3 (1R,2R)-{2-[4-(2,3-dimethyl-phenyl)-piperazin-1-yl]-1,2-dihydro-naphthalen-1-yl}-carbamic acid tert-butyl ester 
• 1118794-04-9 C₂₂H₂₅N₃O₂ 
• 1220831-49-1 2-{3-[4-(2,3-dimethylphenyl)piperazin-1-yl]propyl}isoindole-1,3-dione 
• 1026956-56-8 4-(2,3-dimethylphenyl)-1-piperazinebutanenitrile 
• 1334799-73-3 2-[4-(2,3-dimethylphenyl)piperazin-1-yl]-N,N-diphenylacetamide 

Relevant articles and documents

Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands

Two series of hybrid analogues were designed, synthesized, and evaluated as a novel class of selective ligands for the dopamine D3 receptor. Binding affinities of target compounds were determined (using the method of radioligand binding assay). Compared to comparator agent BP897, compounds 2a and 2c were found to demonstrate a considerable binding affinity and selectivity for D3 receptor, and especially compound 2h was similarly potent and more selective D3R ligand than BP897, a positive reference. Thus, they may provide valuable information for the discovery and development of highly potent dopamine D3 receptor ligands with outstanding selectivity.

Fused heterocyclic compounds and pharmaceutical applications thereof

The present invention relates to a fused heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive, and a medicament containing a compound of the formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof. The compound of the present invention is a useful antipsychotic agent effective not only for positive symptoms centering on hallucination and delusion characteristic of the acute stage of schizophrenia, but also negative symptoms of apathy, abulia and autism. The inventive compound is expected to make a highly safe antipsychotic agent associated with less side effects, such as extrapyramidal symptoms and endocrine disturbance, which are observed when a conventional antipsychotic agent having a D2receptor blocking action is administered. Therefore, the inventive compound can be used as a therapeutic agent for the diseases such as schizophrenia.